[Form 4] BIO-TECHNE Corp Insider Trading Activity
Bio-Techne (TECH) director John L. Higgins filed a Form 4 reporting equity awards dated 10/30/2025.
Rhea-AI Filing Summary
Bio-Techne (TECH) director John L. Higgins filed a Form 4 reporting equity awards dated 10/30/2025. He acquired 1,640 shares of common stock at $0, bringing his directly held common stock to 66,876 shares after the transaction. He was also granted stock options for 3,777 shares with an exercise price of $60.96, expiring on 10/30/2035. The options vest on the earlier of the one‑year anniversary of the grant date or Bio‑Techne’s 2026 annual meeting of shareholders.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 5,417 shares
Grant/Award
11 txns
Insider
HIGGINS JOHN L
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 3,777 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 1,640 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 67,321 contracts for 63,544 underlying shares (Direct);
Common Stock — 66,876 shares (Direct)
Footnotes (1)
- F1. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
FAQ
What did Bio‑Techne (TECH) disclose in this Form 4?
Director John L. Higgins reported acquiring 1,640 common shares at $0 and receiving options for 3,777 shares at an exercise price of $60.96 on 10/30/2025.
What are the terms of the new stock options reported by TECH?
The options cover 3,777 shares, have a $60.96 exercise price, and expire on 10/30/2035.
When do the new Bio‑Techne (TECH) options vest?
They vest on the earlier of the one‑year anniversary of the grant date or the company’s 2026 annual meeting.
Is the ownership reported as direct or indirect for TECH?
Both the common stock and the new option grant are reported as Direct (D) ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.
